Silencing glycogen synthase kinase-3β (GSK-3β) with low expression in breast cancer can upregulate nuclear factor erythroid 2-related factor 2 (Nrf2) and GPX4 expression, inhibit tumor cell ferroptosis, and promote progression (133). Here, GSK3B is linked to neoplasm.